Althea Technologies has been awarded a cGMP manufacturing contract to produce a DNA-based HIV-1 vaccine. The contract, awarded by Advanced BioScience Laboratories, Inc. (ABL), is under a master agreement with the National Institutes of Health (NIH) and funded by the National Institute of Allergy and Infectious Diseases (NIAID). The $911,549 in funding for Althea’s production of the vaccine is provided in its entirety by the NIAID and NIH. The contract will support Althea’s efforts fo...